Cardiovascular pharmacogenomics and individualized drug therapy

Nature Reviews Cardiology

Volumn 6, Issue 10, 2009, Pages 632-638

  Pereira, Naveen L ^a   Weinshilboum, Richard M ^b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

CARDIOVASCULAR DISEASE; GENETIC SCREENING; GENETIC VARIABILITY; GENETICS; GENOTYPE; HUMAN; PATIENT SELECTION; PEDIGREE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PHENOTYPE; REVIEW;

CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HUMANS; INDIVIDUALIZED MEDICINE; PATIENT SELECTION; PEDIGREE; PHARMACOGENETICS; PHENOTYPE;

EID: 79958085599     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2009.154     Document Type: Article

References (46)

1. Scriver, C. R. & Childs, B. (eds)Garrod’s InbornFactors in Disease(Oxford University Press, New York, 1989).[Oxford Monographs onMedical Genetics vol. 16].
2. Motulsky, A. G. Drug reactions enzymes, andbiochemical genetics.JAMA165, 835-837(1957).
3. Vesell, E. S. & Page, J. G. Genetic control ofdrug levels in man: antipyrine.Science161, 72-73 (1968).
4. Kalow, W. & Gunn, D. R. The relationshipbetween dose of succinylcholine and duration of apnea in man.J. Pharmacol. Exp. Ther.120, 203-214 (1957).
5. Kalow, W. & Gunn, D. R. Some statistical dataon atypical cholinesterase of human serum.Ann. Hum. Genet.23, 239-250 (1959).
6. Lockridge, O. inPharmacogenetics of DrugMetabolism: International Encyclopedia ofPharmacology and Therapeutics(ed. Kalow, W.)15-50 (Pergamon Press, New York, 1992).
7. Pearson, T. A. & Manolio, T. A. How to interpreta genome-wide association study.JAMA299, 1335-1344 (2008).
8. Reidenberg, M. M., Drayer, D. E., Levy, M. & Warner, H. Polymorphic acetylation procainamide in man.Clin. Pharmacol. Ther. 17, 722-730 (1975).
9. Perry, H. M. Jr., Tan, E. M., Carmody, S. &Sakamoto, A. Relationship of acetyl transferaseactivity to antinuclear antibodies and toxicsymptoms in hypertensive patients treated with hydralazine.J. Lab. Clin. Med.76, 114-125(1970).
10. Price Evans, D. A. inPharmacogenetics of DrugMetabolism: International Encyclopedia of Pharmacology and Therapeutics(ed. Kalow, W.) 95-178 (Pergamon Press, New York, 1992).
11. Eichelbaum, M., Spannbrucker, N., Steincke, B. & Dengler, H. J. Defective N-oxidation of sparteine in man: a new pharmacogeneticdefect.Eur. J. Clin. Pharmacol.16, 183-187(1979).
12. Lennard, M. S.et al.Oxidation phenotype—amajor determinant of metoprolol metabolismand response.N. Engl. J. Med.307, 1558-1560(1982).
13. Gonzalez, F. J.et al.Human debrisoquine4-hydroxylase (P450IID1): cDNA and deducedamino acid sequence and assignment of theCYP2D locus of chromosome 22.Genomics2, 174-179 (1988).
14. Kimura, S., Umeno, M., Skoda, R. C., Meyer, U. A.& Gonzalez, F. J. The human debrisoquine4-hydroxylase (CYP2D) locus: sequence andidentification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.Am. J. Hum. Genet.45, 889-904 (1989).
15. Johansson, I.et al.Inherited amplification of anactive gene in the cytochrome P450 CYP2Dlocus as a cause of ultrarapid metabolism ofdebrisoquine.Proc. Natl Acad. Sci. USA 90, 11825-11829 (1993).
16. Akulli, E.et al.Frequent distribution ofultrarapid metabolizers of debrisoquine in anEthiopian population carrying duplicated andmultiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther.278, 441-446 (1996).
17. Mega, J. L.et al.Cytochrome p-450polymorphisms and response to clopidogrel. N. Engl. J. Med.360, 354-362 (2008).
18. Roger, V. L.et al.Trends in heart failureincidence and survival in a community-basedpopulation.JAMA292, 344-350 (2004).
19. Bardy G. H.et al.Amiodarone or an implantablecardioverter-defibrillator for congestive heartfailure.N. Engl. J. Med.352, 225-237 (2005).
20. The Beta-Blocker Evaluation of Survival TrialInvestigators. A trial of the beta-blockerbucindolol in patients with advanced chronicheart failure.N. Engl. J. Med.344, 1659-1667(2001).
21. Taylor, M. R. Pharmacogenetics of the humanbeta-adrenergic receptors.Pharmacogenomics J.7, 29-37 (2007).
22. Moore, J. D., Mason, D. A., Green, S. A., Hsu, J. & Liggett, S. B. Racial differences in the frequencies of cardiac beta(1)-adrenergicreceptor polymorphisms: analysis of c145A>Gand c1165G>C.Hum. Mutat.14, 271 (1999).
23. Liggett, S. B.et al.A polymorphism within aconserved beta(1)-adrenergic receptor motifalters cardiac function and beta-blocker response in human heart failure.Proc. NatlAcad. Sci. USA103, 11288-11293 (2006).
24. Small, K. M., Forbes, S. L., Rahman, F., Bridges, K. M. & Liggett, S. B. A four amino aciddeletion polymorphism in the third intracellularloop of the human alpha 2C-adrenergic receptorconfers impaired coupling to multiple effectors.J. Biol. Chem.275, 23059-23064 (2000).
25. Small, K. M., Wagoner, L. E., Levin, A. M., Kardia, S. L. & Liggett, S. B. Synergistic polymorphisms of beta1- and alpha2C-adrenergicreceptors and the risk of congestive heart failure.N. Engl. J. Med.347, 1135-1142 (2002).
26. Liggett, S. B.et al.A GRK5 polymorphism thatinhibits beta-adrenergic receptor signaling isprotective in heart failure.Nat. Med.14, 510-517 (2008).
27. Budnitz, D. S., Shehab, N., Kegler, S. R. &Richards, C. L. Medication use leading toemergency department visits for adverse drugevents in older adults.Ann. Intern. Med.147, 755-765 (2007).
28. O’Reilly, R. A., Aggeler, P M., Hoag, M. S., Leong, L. S. & Kropatkin, M. L. Hereditary transmission of exceptional resistance tocoumarin anticoagulant drugs. The first reportedkindred.N. Engl. J. Med.271, 809-815 (1964).
29. Daly, A. K. & King, B. P. Pharmacogenetics oforal anticoagulants.Pharmacogenetics13, 247-252 (2003).
30. Aithal, G. P, Day, C. P, Kesteven, P J. & Daly, A. K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin doserequirement and risk of bleeding complications.Lancet353, 717-719 (1999).
31. Rost, S.et al.Mutations in VKORC1 causewarfarin resistance and multiple coagulationfactor deficiency type 2.Nature427, 537-541(2004).
32. Rieder, M. J. etal.Effect of VKORC1 haplotypeson transcriptional regulation and warfarin dose.N. Engl. J. Med.352, 2285-2293 (2005).
33. Schwarz, U. I.et al.Genetic determinants ofresponse to warfarin during initialanticoagulation.N. Engl. J. Med.358, 999-1008(2008).
34. Lesko, L. J. The critical path of warfarin dosing:finding an optimal dosing strategy usingpharmacogenetics.Clin. Pharmacol. Ther.84, 301-303 (2008).
35. International Warfarin PharmacogeneticsConsortiumet al.Estimation of the warfarindose with clinical and pharmacogenetic data. N. Engl. J. Med.360, 753-764 (2009). http://clinicaltrials.gov/ct2/show/NCT00839657
36. The SEARCH Collaborative Group et al.SLCO1B1 variants and statin-inducedmyopathy—a genomewide study.N. Engl. J. Med.359, 789-799 (2008).
37. Mangravite, L. M. & Krauss, R. M.Pharmacogenomics of statin response. Curr. Opin. Lipidol.18, 409-414 (2007).
38. Zuccaro, Pet al.Tolerability of statins is notlinked to CYP450 polymorphisms, but reducedCYP2D6 metabolism improves cholesteraemicresponse to simvastatin and fluvastatin.Pharmacol. Res.55, 310-317 (2007).
39. Wang, L. & Weinshilboum, R. M.Pharmacogenomics: candidate geneidentification, functional validation andmechanisms.Hum. Mol. Genet.17, R174-R179(2008).
40. Li, L.et al.Gemcitabine and cytosinearabinoside cytotoxicity: association withlymphoblastoid cell expression.Cancer Res. 68, 7050-7058 (2008).
41. Pei, H.et al.FKBP51 acts as a scaffoldingprotein to regulate Akt phosphorylation.CancerCell(in press).
42. Weinstein, J. N. Spotlight on molecular profiling:‘Integromic’ analysis of the NCI-60 cancer celllines.Mol. Cancer Ther.5, 2601-2605 (2006).
43. Hughes, D. A. & Pirmohamed, M. Warfarinpharmacogenetics: economic considerations.Pharmacoeconomics25, 899-902 (2007).
44. Eckman, M. H., Rosand, J., Greenberg, S. M. & Gage, B. F. Cost-effectiveness of using pharmacogenetic information in warfarin dosingfor patients with nonvalvular atrial fibrillation.Ann. Intern. Med.150, 73-83 (2009).
45. Hudson, K. L., Holohan, M. K. & Collins, F. S.Keeping pace with the times—the GeneticInformation Nondiscrimination Act of 2008. N. Engl. J. Med.358, 2661-2663 (2008).
46. Jones, M. Francis Collins Addresses State ofPersonalized edicine.GenomeWeb[online], http://www.genomeweb.com/dxpgx/francis-collins-addresses-state-personalized-medicine(2009).